NeOnc Technologies Secures Rare Pediatric Disease Designation
Based in Westlake Village, NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a pioneering clinical-stage medical biotechnology company, has achieved a significant milestone following the announcement from the U.S. Food and Drug Administration (FDA). The FDA has granted Rare Pediatric Disease Designation to their leading drug candidate, NEO100 (perillyl alcohol), aimed at treating pediatric-type diffuse high-grade gliomas. This condition is notably severe and poses a significant threat to children and adolescents.
Understanding the Importance of the Designation
This designation, issued per Section 529(a)(3) of the Federal Food, Drug, and Cosmetic Act, acknowledges the critical need for effective treatment options for this rare type of brain cancer. It highlights that the disease predominantly impacts young patients, encompassing individuals from birth up to 18 years of age, aligning with the FDA’s definition of a "rare disease or condition." The designation not only enhances the urgency of advancing novel therapies but also underscores the commitment of NeOnc Technologies to innovate in the field of pediatric oncology.
Impact on Pediatric Cancer Treatment
Amir Heshmatpour, Executive Chairman of NeOnc Technologies, expressed optimism regarding this designation, stating, "This milestone is crucial as we strive to develop therapies for children grappling with this aggressive form of brain cancer. Our resolve to move NEO100 through clinical development reflects our dedication to offering hope to families affected by this challenging condition."
Collaboration for Advancement
Dr. Thomas Chen, the company's CEO and Chief Science Officer, remarked on the validation that this designation brings to their commitments. He noted, "Receiving the Rare Pediatric Disease Designation for NEO100 is a significant leap in our mission to offer effective treatment options for pediatric patients facing the dire circumstances of diffuse high-grade gliomas. Our research is validated, further strengthening our determination to deliver innovative therapies that can profoundly impact children's lives."
Understanding the Rare Pediatric Disease Priority Review Voucher Program
The Rare Pediatric Disease Designation enables NeOnc Technologies to qualify for a Rare Pediatric Disease Priority Review Voucher (PRV) upon approval of NEO100's marketing application. The PRV program aims to expedite regulatory review processes for new drugs catering to rare pediatric diseases, ultimately encouraging their development. These vouchers can be extremely valuable, offering strategic and financial incentives based on current market conditions.
Strategic Value of PRVs
Heshmatpour further highlighted the growing market for PRVs, stating, "This potential asset enhances our progress and holds considerable worth especially for our community of patients and families we are here to support." As NeOnc Technologies forges ahead with NEO100, the company is committed to collaboration with the FDA, engage with the medical community, and strive for partnerships with researchers and patient advocacy organizations to enhance the landscape of pediatric brain cancer treatments.
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies is a clinical-stage life sciences company dedicated to the development and commercialization of central nervous system therapeutics. Their focus is on overcoming challenges related to the blood-brain barrier, enabling better treatment possibilities for neuro-oncological patients. The company’s NEO™ drug development platform has resulted in a strong portfolio of innovative drug candidates that boast patent protections until 2038. With promising results from laboratory tests and ongoing clinical trials for NEO100 and NEO212, which are currently advancing under FDA Fast-Track designation, NeOnc Technologies is positioned at the forefront of oncological and neurological therapeutic development.
Frequently Asked Questions
What is the Rare Pediatric Disease Designation?
The Rare Pediatric Disease Designation is an FDA program aimed at accelerating the development of therapies for conditions affecting children, recognizing the urgent need for effective treatments.
How does NEO100 function in treating high-grade gliomas?
NEO100 utilizes perillyl alcohol, which shows potential effectiveness against pediatric-type diffuse high-grade gliomas by targeting the aggressive nature of these tumors.
Why is the PRV program important for NeOnc Technologies?
The PRV program provides incentives for companies to develop drugs for rare diseases, allowing them to expedite their applications through the FDA, optimizing their market potential.
What are NeOnc’s future plans regarding NEO100?
NeOnc Technologies plans to continue progressing NEO100 through clinical trials while collaborating with medical professionals and advocacy groups to ensure rapid and effective treatment options for children.
Who can be contacted for more information about NeOnc Technologies?
For inquiries, Patrick Walters, the Chief Operations Officer, can be contacted at info@neonc.com, or through their official website for the latest updates and information.
